Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Website: senseibio.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -50.9% (LTM)

Entry Point: Share price is 237.7% higher than minimum and 86.9% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: SNSE
Share price, USD:  (+8.5%)1.79
year average price 0.9764  


year start price 1.5800 2023-05-08

min close price 0.5301 2023-10-30

max close price 1.7900 2024-05-03

current price 1.7900 2024-05-06
Common stocks: 30 703 295

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 55
Net Debt ($m): -7
EV (Enterprise Value): 48
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-10-25GlobeNewsWire

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

2023-04-13GlobeNewsWire

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-07 2023-08-03 2023-05-09 2023-03-29 2022-11-08 2022-05-10
acceptedDate 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q1
revenue 3M 0 0 0 0 0 0
costOfRevenue 135 000 455 000 491 000 0 0 0 0
grossProfit 3M -455 000 -491 000 0 0 0 0
grossProfitRatio 0.953 0 0 0 0 0 0
researchAndDevelopmentExpenses 4M 4M 5M 5M 7M 9M 7M
generalAndAdministrativeExpenses 4M 4M 5M 6M 6M 5M 5M
sellingAndMarketingExpenses -135 000 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 4M 5M 6M 6M 5M 5M
otherExpenses -67 000 613 000 68 000 831 000 2M 0 0
operatingExpenses 8M 8M 10M 11M 13M 14M 12M
costAndExpenses 8M 8M 10M 11M 13M 14M 12M
interestIncome 826 000 877 000 952 000 969 000 609 000 515 000 310 000
interestExpense 31 000 33 000 38 000 42 000 -206 000 10000.000 243 000
depreciationAndAmortization 135 000 332 000 332 000 358 000 -1M 877 000 334 000
ebitda -8M -8M -9M -11M -14M -13M -12M
ebitdaratio -2.813 0 0 0 0 0 0
operatingIncome -8M -8M -10M -11M -13M -14M -12M
operatingIncomeRatio -2.861 0 0 0 0 0 0
totalOtherIncomeExpensesNet 727 999 613 000 -123 000 831 000 816 000 525 000 82 000
incomeBeforeTax -7M -7M -9M -10M -12M -13M -12M
incomeBeforeTaxRatio -2.605 0 0 0 0 0 0
incomeTaxExpense 1M -332 000 106 000 -1M 209 000 -525 000 0
netIncome -7M -7M -9M -9M -12M -13M -12M
netIncomeRatio -2.605 0 0 0 0 0 0
eps -0.300 -0.280 -0.310 -0.290 -0.410 -0.420 -0.400
epsdiluted -0.300 -0.280 -0.310 -0.290 -0.410 -0.420 -0.400
weightedAverageShsOut 25M 26M 31M 31M 31M 31M 31M
weightedAverageShsOutDil 25M 26M 31M 31M 31M 31M 31M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-07 2023-08-03 2023-05-09 2023-03-29 2022-11-08 2022-05-10
acceptedDate 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q1
cashAndCashEquivalents 13M 11M 10M 8M 18M 11M 9M
shortTermInvestments 53M 61M 69M 87M 89M 105M 128M
cashAndShortTermInvestments 66M 72M 79M 8M 18M 117M 136M
netReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
otherCurrentAssets 1M 318 000 252 000 454 000 344 000 336 000 3M
totalCurrentAssets 67M 72M 81M 99M 109M 118M 139M
propertyPlantEquipmentNet 7M 8M 8M 9M 10M 10M 11M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 85 999 2M 86 000 81 000 63 000 45 000 39 000
totalNonCurrentAssets 7M 10M 9M 9M 10M 10M 11M
otherAssets 1.000 0 0 0 -1000.000 0 0
totalAssets 74M 82M 90M 108M 118M 129M 150M
accountPayables 2M 3M 2M 0 0 5M 0
shortTermDebt 2M 2M 2M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 -3M -2M 0 0 0 0
otherCurrentLiabilities 2M 4M 3M 5M 7M 2M 6M
totalCurrentLiabilities 6M 6M 5M 8M 9M 8M 8M
longTermDebt 4M 4M 5M 5M 6M 6M 7M
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 66 999 67 000 72 000 34 000 0 -405 000 0
totalNonCurrentLiabilities 4M 4M 5M 6M 6M 6M 7M
otherLiabilities 1.000 0 0 0 0 0 0
capitalLeaseObligations 4M 7M 7M 8M 8M 8M 9M
totalLiabilities 9M 11M 10M 13M 15M 15M 15M
preferredStock 0 0 0 0 0 0 0
commonStock 3000.000 2000.000 3000.000 3000.000 3000.000 3000.000 3000.000
retainedEarnings -232M -224M -217M -208M -198M -186M -162M
accumulatedOtherComprehensiveIncomeLoss -209 000 -402 000 -549 000 -823 000 -1M -1M -899 000
othertotalStockholdersEquity 297M 296M 297M 304M 302M 301M 298M
totalStockholdersEquity 65M 71M 79M 95M 103M 114M 135M
totalEquity 65M 71M 79M 95M 103M 114M 135M
totalLiabilitiesAndStockholdersEquity 74M 82M 90M 108M 118M 129M 150M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 74M 82M 90M 108M 118M 129M 150M
totalInvestments 53M 61M 69M 87M 89M 105M 0
totalDebt 6M 7M 7M 8M 8M 8M 9M
netDebt -7M -5M -3M -358 000 -10M -3M 349 000
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-07 2023-08-03 2023-05-09 2023-03-29 2022-11-08 2022-05-10
acceptedDate 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q1
netIncome -7M -7M -9M -10M -12M -13M -12M
depreciationAndAmortization 135 000 332 000 332 000 358 000 351 000 342 000 334 000
deferredIncomeTax 356 000 -214 000 -142 000 0 0 0 0
stockBasedCompensation 1M 1M 1M 1M 1M 1M 2M
changeInWorkingCapital -400 000 979 000 -2M -3M 655 000 5M -667 000
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables -781 000 471 000 -2M 242 000 2M 0 0
otherWorkingCapital 381 000 508 000 548 000 -3M -1M 5M -1M
otherNonCashItems 62 000 318 000 353 000 64 000 253 000 247 000 473 000
netCashProvidedByOperatingActivities -6M -5M -9M -12M -10M -7M -11M
investmentsInPropertyPlantAndEquipment 0 0 -29 000 -151 000 -71 000 -250 000 -19 000
acquisitionsNet -166 000 0 157 000 0 0 0 0
purchasesOfInvestments -3M -9M -2000.000 -10M 18M -22M -8M
salesMaturitiesOfInvestments 11M 17M 19M 12M -2M 31M 20M
otherInvestingActivites 166 000 8312.000 0 9000.000 71 000 15 000 0
netCashUsedForInvestingActivites 8M 8M 20M 2M 16M 9M 12M
debtRepayment -196 000 -190 000 -189 000 -186 000 -177 000 -163 000 -133 000
commonStockIssued 48 000 0 0 0 238 000 0 0
commonStockRepurchased -252 000 -2M -8M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -31 000 -10 132 31 000 -76 000 -185 000 0 252 000
netCashUsedProvidedByFinancingActivities -431 000 -3M -8M -262 000 -124 000 -163 000 119 000
effectOfForexChangesOnCash 12M 0 -12M 0 0 0 0
netChangeInCash 2M 1M 2M -10M 6M 2M 2M
cashAtEndOfPeriod 13M 11M 10M 8M 18M 11M 9M
cashAtBeginningOfPeriod 11M 10M 8M 18M 11M 10M 7M
operatingCashFlow -6M -5M -9M -12M -10M -7M -11M
capitalExpenditure 0 0 -29 000 -151 000 -71 000 -250 000 -19 000
freeCashFlow -6M -5M -9M -12M -10M -7M -11M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-28 12:30 ET
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
2024-02-07 12:30 ET
Sensei Biotherapeutics to Present at Upcoming Conferences
2024-01-04 12:30 ET
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
2023-11-07 12:30 ET
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2023-11-03 20:05 ET
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
2023-11-01 11:30 ET
Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
2023-10-25 13:05 ET
Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
2023-10-23 11:30 ET
Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
2023-09-27 11:30 ET
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
2023-09-21 11:30 ET
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
2023-09-13 11:30 ET
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Im...
2023-08-30 11:30 ET
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
2023-08-03 11:30 ET
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2023-08-02 11:30 ET
Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
2023-06-13 11:30 ET
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
2023-06-01 11:30 ET
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
2023-05-31 11:30 ET
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
2023-05-09 11:30 ET
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
2023-04-20 11:30 ET
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
2023-04-18 20:05 ET
Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-04-13 11:30 ET
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
2023-03-30 11:30 ET
Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
2023-03-28 11:30 ET
Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
2023-03-21 11:30 ET
Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
2023-03-14 20:35 ET
Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023
2023-03-07 22:15 ET
Sensei Biotherapeutics Adopts Stockholder Rights Agreement
2023-03-06 12:30 ET
Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
2023-02-21 12:30 ET
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
2023-02-16 12:30 ET
Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
2023-02-14 12:30 ET
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
2023-02-06 12:30 ET
Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
2023-01-05 12:30 ET
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
2022-12-12 16:42 ET
Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)
2022-12-08 12:30 ET
Sensei Biotherapeutics Provides Update on Strategic Priorities
2022-11-22 12:30 ET
Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-21 12:30 ET
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
2022-11-21 11:00 ET
Significant Investor in Sensei Biotherapeutics, Inc. Urges Board to Seek Shareholder Mandate
2022-11-10 14:00 ET
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
2022-11-08 12:30 ET
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
2022-11-07 12:30 ET
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”
2022-11-02 11:30 ET
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
2022-10-05 12:05 ET
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
2022-09-30 20:05 ET
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
2022-09-21 20:05 ET
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
2022-08-31 11:30 ET
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
2022-08-23 11:30 ET
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
2022-08-09 11:30 ET
Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2022-06-01 11:30 ET
Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer
2022-05-25 11:30 ET
Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference
2022-05-10 11:30 ET
Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
2022-03-10 12:30 ET
Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
2022-03-09 21:05 ET
Sensei Biotherapeutics Appoints William Ringo, MBA, as Chair of Board of Directors
2022-03-03 12:30 ET
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference
2022-02-11 12:30 ET
Sensei Biotherapeutics to Participate in Citi’s 2022 Virtual Immuno-Oncology Summit
2022-01-06 13:00 ET
Sensei Biotherapeutics Announces Executive Promotions
2021-12-16 14:01 ET
Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award
2021-12-13 21:01 ET
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
2021-11-19 21:02 ET
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
2021-11-12 12:02 ET
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a pH-Selective Anti-VISTA Antibody, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
2021-11-09 13:54 ET
Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights
2021-11-03 13:01 ET
Sensei Biotherapeutics to Participate in the Berenberg Virtual U.S. CEO Conference on Tuesday, November 9, 2021
2021-10-01 12:05 ET
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2021-08-04 11:45 ET
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
2021-08-02 12:01 ET
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
2021-06-28 20:05 ET
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal Antibody and Nanobody Programs
2021-05-19 21:03 ET
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck
2021-05-12 11:41 ET
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
2021-05-05 12:05 ET
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
2021-04-05 12:00 ET
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D. to its Board of Directors
2021-03-25 12:00 ET
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update
2021-03-22 12:00 ET
Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index
2021-03-09 13:30 ET
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
2021-02-10 21:55 ET
Sensei Biotherapeutics Announces Closing of Initial Public Offering
2021-02-09 16:08 ET
Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy
2021-02-04 01:44 ET
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-02-29 16:30 ET
Sensei Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-28 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q4
SEC form 8
2024-02-28 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q4
SEC form 10
2023-11-07 16:40 ET
Sensei Biotherapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-07 07:35 ET
Sensei Biotherapeutics, Inc. published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-03 16:32 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-03 08:45 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-10 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-27 09:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-23 16:30 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-15 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q1
SEC form 10
2023-03-29 07:31 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-28 08:26 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-28 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-13 07:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-10 09:29 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-07 17:30 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-06 07:30 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-09 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 6
2022-12-08 08:18 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-10 09:05 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-08 16:32 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-08 08:08 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 6
2022-09-30 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q2
SEC form 6
2022-08-31 07:57 ET
Sensei Biotherapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-09 17:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 07:46 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 6
2022-06-14 16:27 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 17:03 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 07:39 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:13 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-20 08:06 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-15 07:01 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-15 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-10 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-09 16:23 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-10 08:32 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2021-12-06 08:32 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-16 16:03 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 17:02 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-09 09:23 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-09-08 08:01 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-11 16:12 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-04 08:30 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-02 16:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-02 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-28 16:10 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 16:05 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 16:19 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-05-12 08:20 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-05-03 06:33 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-05 08:50 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-05 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-03-30 06:15 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-03-25 08:50 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-02-11 07:00 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-02-03 20:56 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4